Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lymphangiogenesis | 8 | 2022 | 171 | 2.070 |
Why?
|
Neovascularization, Pathologic | 29 | 2018 | 2631 | 2.020 |
Why?
|
Neuropilin-2 | 5 | 2022 | 55 | 1.330 |
Why?
|
Neuropilin-1 | 6 | 2014 | 90 | 1.220 |
Why?
|
Neoplasm Metastasis | 19 | 2021 | 4893 | 1.130 |
Why?
|
Neuropilins | 5 | 2014 | 12 | 1.100 |
Why?
|
Lymphatic Vessels | 6 | 2023 | 355 | 0.860 |
Why?
|
Vascular Endothelial Growth Factor A | 16 | 2021 | 3513 | 0.840 |
Why?
|
Neovascularization, Physiologic | 6 | 2018 | 1375 | 0.760 |
Why?
|
Epidermis | 4 | 2014 | 538 | 0.670 |
Why?
|
Lymphatic Metastasis | 7 | 2015 | 2887 | 0.640 |
Why?
|
Endothelial Cells | 15 | 2023 | 3584 | 0.590 |
Why?
|
Interferon-beta | 9 | 2003 | 346 | 0.590 |
Why?
|
Semaphorin-3A | 2 | 2014 | 39 | 0.530 |
Why?
|
Eicosanoids | 5 | 2021 | 284 | 0.530 |
Why?
|
Nerve Tissue Proteins | 7 | 2019 | 4392 | 0.520 |
Why?
|
Lymphatic System | 2 | 2014 | 250 | 0.510 |
Why?
|
Receptors, Neurokinin-1 | 1 | 2016 | 133 | 0.490 |
Why?
|
Lymphedema | 2 | 2023 | 525 | 0.470 |
Why?
|
Angiogenesis Inhibitors | 5 | 2016 | 2056 | 0.470 |
Why?
|
Epithelial-Mesenchymal Transition | 3 | 2015 | 752 | 0.450 |
Why?
|
Muscle, Smooth | 2 | 2022 | 931 | 0.450 |
Why?
|
Cell Movement | 13 | 2020 | 5194 | 0.440 |
Why?
|
Neoplasms | 21 | 2024 | 22340 | 0.440 |
Why?
|
Epoxide Hydrolases | 5 | 2021 | 121 | 0.430 |
Why?
|
Muscle Contraction | 2 | 2022 | 1206 | 0.420 |
Why?
|
Adaptor Proteins, Vesicular Transport | 3 | 2021 | 298 | 0.410 |
Why?
|
Liver Regeneration | 1 | 2014 | 214 | 0.410 |
Why?
|
Semaphorins | 3 | 2009 | 96 | 0.410 |
Why?
|
Thrombospondin 1 | 4 | 2022 | 256 | 0.410 |
Why?
|
Regeneration | 2 | 2018 | 1517 | 0.380 |
Why?
|
Microcirculation | 3 | 2021 | 1280 | 0.380 |
Why?
|
Membrane Proteins | 7 | 2016 | 7851 | 0.380 |
Why?
|
Epithelium | 1 | 2016 | 1599 | 0.370 |
Why?
|
Capillary Permeability | 3 | 2016 | 768 | 0.350 |
Why?
|
Mouth Neoplasms | 1 | 2016 | 594 | 0.350 |
Why?
|
Cytoskeleton | 3 | 2012 | 1178 | 0.340 |
Why?
|
Carcinoma, Squamous Cell | 4 | 2016 | 4044 | 0.340 |
Why?
|
Skin Neoplasms | 6 | 2016 | 5849 | 0.320 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 4 | 2018 | 548 | 0.320 |
Why?
|
Animals | 69 | 2023 | 168764 | 0.320 |
Why?
|
Mice | 55 | 2023 | 81819 | 0.320 |
Why?
|
Neoplasm Invasiveness | 5 | 2014 | 3602 | 0.290 |
Why?
|
Neoplasms, Experimental | 5 | 2019 | 1229 | 0.280 |
Why?
|
Neoplastic Stem Cells | 1 | 2015 | 1352 | 0.280 |
Why?
|
Wound Healing | 1 | 2018 | 2792 | 0.280 |
Why?
|
Mice, Inbred BALB C | 9 | 2019 | 6220 | 0.280 |
Why?
|
rho-Associated Kinases | 2 | 2023 | 291 | 0.280 |
Why?
|
Cell Line, Tumor | 23 | 2023 | 17075 | 0.270 |
Why?
|
Interleukin-1beta | 1 | 2013 | 1028 | 0.270 |
Why?
|
Trachea | 1 | 2013 | 1085 | 0.270 |
Why?
|
Receptors, Growth Factor | 1 | 2007 | 324 | 0.270 |
Why?
|
Urinary Bladder | 3 | 2020 | 1154 | 0.260 |
Why?
|
Graves Ophthalmopathy | 2 | 2020 | 135 | 0.260 |
Why?
|
Mice, Transgenic | 10 | 2017 | 9550 | 0.250 |
Why?
|
Cell Differentiation | 6 | 2016 | 11641 | 0.240 |
Why?
|
Mice, Nude | 16 | 2014 | 3618 | 0.240 |
Why?
|
Proteoglycans | 4 | 2014 | 793 | 0.220 |
Why?
|
Blotting, Northern | 4 | 2014 | 1546 | 0.220 |
Why?
|
Immunohistochemistry | 11 | 2017 | 11022 | 0.220 |
Why?
|
Docosahexaenoic Acids | 3 | 2019 | 916 | 0.210 |
Why?
|
Recombinant Proteins | 7 | 2018 | 6493 | 0.210 |
Why?
|
Cell Proliferation | 16 | 2021 | 10429 | 0.210 |
Why?
|
Colonic Neoplasms | 5 | 2023 | 2531 | 0.210 |
Why?
|
Blotting, Western | 4 | 2014 | 5020 | 0.210 |
Why?
|
Melanocytes | 3 | 2017 | 515 | 0.200 |
Why?
|
Heparin | 2 | 2021 | 1630 | 0.200 |
Why?
|
Lung | 6 | 2021 | 10033 | 0.200 |
Why?
|
Receptors, Prostaglandin E, EP4 Subtype | 1 | 2021 | 44 | 0.190 |
Why?
|
Urokinase-Type Plasminogen Activator | 2 | 2014 | 323 | 0.190 |
Why?
|
Keratinocytes | 4 | 2014 | 863 | 0.190 |
Why?
|
rhoA GTP-Binding Protein | 2 | 2012 | 234 | 0.180 |
Why?
|
Liver | 4 | 2023 | 7562 | 0.180 |
Why?
|
Cytokines | 6 | 2023 | 7421 | 0.180 |
Why?
|
Oxazolone | 1 | 2020 | 59 | 0.180 |
Why?
|
Gastrointestinal Motility | 1 | 2022 | 235 | 0.170 |
Why?
|
Skin | 4 | 2005 | 4489 | 0.170 |
Why?
|
Mice, Inbred C57BL | 14 | 2021 | 22332 | 0.170 |
Why?
|
In Situ Hybridization | 4 | 2014 | 1886 | 0.170 |
Why?
|
Cyclooxygenase 2 | 2 | 2020 | 594 | 0.170 |
Why?
|
Mammary Neoplasms, Animal | 1 | 2021 | 122 | 0.170 |
Why?
|
Phenotype | 3 | 2015 | 16721 | 0.160 |
Why?
|
Antineoplastic Agents | 7 | 2021 | 13648 | 0.160 |
Why?
|
Humans | 72 | 2024 | 765968 | 0.150 |
Why?
|
Ketorolac | 1 | 2019 | 95 | 0.150 |
Why?
|
Hemangioma, Capillary | 1 | 1999 | 64 | 0.150 |
Why?
|
Vascular Endothelial Growth Factor Receptor-3 | 1 | 2018 | 117 | 0.150 |
Why?
|
Macrophages | 9 | 2021 | 5772 | 0.150 |
Why?
|
Neoplasm Proteins | 3 | 2021 | 3596 | 0.150 |
Why?
|
Signal Transduction | 10 | 2021 | 23601 | 0.150 |
Why?
|
Prostatic Neoplasms | 5 | 2014 | 11083 | 0.140 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 5 | 2014 | 4562 | 0.140 |
Why?
|
Pneumonectomy | 3 | 2021 | 1128 | 0.140 |
Why?
|
Intercellular Signaling Peptides and Proteins | 2 | 2016 | 1657 | 0.140 |
Why?
|
Cytochrome P-450 Enzyme System | 2 | 2017 | 423 | 0.140 |
Why?
|
Urinary Bladder Neck Obstruction | 1 | 2017 | 82 | 0.140 |
Why?
|
Second Messenger Systems | 1 | 2017 | 204 | 0.130 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2019 | 318 | 0.130 |
Why?
|
Specific Pathogen-Free Organisms | 1 | 2016 | 220 | 0.130 |
Why?
|
Osteopontin | 1 | 2018 | 304 | 0.130 |
Why?
|
Epithelial Cells | 2 | 2018 | 3681 | 0.130 |
Why?
|
Chemokine CCL2 | 2 | 2019 | 602 | 0.130 |
Why?
|
Saposins | 1 | 2016 | 22 | 0.130 |
Why?
|
Ubiquitination | 1 | 2021 | 996 | 0.130 |
Why?
|
Down-Regulation | 5 | 2012 | 2927 | 0.130 |
Why?
|
Metabolic Diseases | 1 | 2022 | 687 | 0.130 |
Why?
|
Fatty Acids | 1 | 2024 | 1806 | 0.130 |
Why?
|
Epoxy Compounds | 2 | 2013 | 136 | 0.130 |
Why?
|
Laminin | 2 | 2014 | 404 | 0.120 |
Why?
|
Skin Pigmentation | 2 | 2014 | 279 | 0.120 |
Why?
|
Core Binding Factor Alpha 2 Subunit | 1 | 2017 | 350 | 0.120 |
Why?
|
Keratin-1 | 1 | 2014 | 2 | 0.120 |
Why?
|
Cell Separation | 1 | 2020 | 1718 | 0.120 |
Why?
|
Ultraviolet Rays | 2 | 2002 | 1102 | 0.120 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 2 | 2016 | 660 | 0.110 |
Why?
|
Colon | 1 | 2022 | 1795 | 0.110 |
Why?
|
Retinal Neovascularization | 1 | 2017 | 289 | 0.110 |
Why?
|
Choroidal Neovascularization | 1 | 2017 | 360 | 0.110 |
Why?
|
Collagen | 3 | 2014 | 2618 | 0.110 |
Why?
|
Gene Knockout Techniques | 1 | 2017 | 798 | 0.110 |
Why?
|
Phagocytosis | 4 | 2021 | 1520 | 0.110 |
Why?
|
Peptides, Cyclic | 1 | 2016 | 390 | 0.110 |
Why?
|
Cells, Cultured | 7 | 2017 | 18973 | 0.110 |
Why?
|
Immunity, Cellular | 1 | 2019 | 1555 | 0.110 |
Why?
|
Transplantation, Heterologous | 6 | 2014 | 2394 | 0.110 |
Why?
|
Sequence Homology, Nucleic Acid | 1 | 2014 | 1056 | 0.110 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2017 | 1132 | 0.110 |
Why?
|
Fluorouracil | 1 | 2018 | 1648 | 0.100 |
Why?
|
Keratin-14 | 2 | 2005 | 57 | 0.100 |
Why?
|
Extracellular Matrix Proteins | 2 | 2014 | 833 | 0.100 |
Why?
|
Cathepsin B | 1 | 2012 | 80 | 0.100 |
Why?
|
Spinal Cord Injuries | 1 | 2020 | 927 | 0.100 |
Why?
|
Disease Models, Animal | 11 | 2020 | 18293 | 0.100 |
Why?
|
Organ Specificity | 2 | 2012 | 1965 | 0.100 |
Why?
|
Diabetes Mellitus, Experimental | 1 | 2018 | 1118 | 0.100 |
Why?
|
Blood Vessels | 2 | 2016 | 1113 | 0.100 |
Why?
|
Models, Biological | 6 | 2018 | 9443 | 0.100 |
Why?
|
Antigens, Ly | 1 | 2013 | 296 | 0.100 |
Why?
|
Integrin alphaVbeta3 | 1 | 2012 | 102 | 0.100 |
Why?
|
Tumor Microenvironment | 4 | 2022 | 3946 | 0.100 |
Why?
|
Neoplasms, Glandular and Epithelial | 1 | 2016 | 488 | 0.090 |
Why?
|
Transfection | 5 | 2008 | 5743 | 0.090 |
Why?
|
Cell Division | 7 | 2004 | 4475 | 0.090 |
Why?
|
Disease Progression | 6 | 2020 | 13632 | 0.090 |
Why?
|
Keratins | 2 | 2005 | 498 | 0.090 |
Why?
|
Interferon-alpha | 3 | 2002 | 910 | 0.090 |
Why?
|
Macrophage-Activating Factors | 1 | 2010 | 21 | 0.090 |
Why?
|
Cell Shape | 1 | 2012 | 373 | 0.090 |
Why?
|
Drug Combinations | 2 | 2014 | 2077 | 0.090 |
Why?
|
Polyethylene Glycols | 2 | 2017 | 1188 | 0.090 |
Why?
|
Sus scrofa | 1 | 2012 | 430 | 0.090 |
Why?
|
Polyglycolic Acid | 1 | 2012 | 406 | 0.090 |
Why?
|
Mice, Knockout | 8 | 2022 | 14448 | 0.090 |
Why?
|
Organoplatinum Compounds | 1 | 2012 | 404 | 0.090 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2021 | 2880 | 0.090 |
Why?
|
Ovarian Neoplasms | 2 | 2019 | 4900 | 0.090 |
Why?
|
Mice, Inbred C3H | 4 | 1998 | 914 | 0.090 |
Why?
|
Gene Expression Regulation, Neoplastic | 5 | 2013 | 8611 | 0.090 |
Why?
|
Carcinoma in Situ | 1 | 2016 | 779 | 0.090 |
Why?
|
Doxorubicin | 1 | 2017 | 2230 | 0.090 |
Why?
|
Cyclic AMP Response Element-Binding Protein | 1 | 2012 | 499 | 0.090 |
Why?
|
Recombinant Fusion Proteins | 1 | 2018 | 3737 | 0.080 |
Why?
|
Preoperative Care | 1 | 2019 | 2267 | 0.080 |
Why?
|
Hep G2 Cells | 2 | 2021 | 379 | 0.080 |
Why?
|
Prodrugs | 1 | 2012 | 273 | 0.080 |
Why?
|
Liver Neoplasms | 3 | 2021 | 4353 | 0.080 |
Why?
|
Nerve Growth Factors | 1 | 2012 | 565 | 0.080 |
Why?
|
Vitamin D-Binding Protein | 1 | 2010 | 129 | 0.080 |
Why?
|
Cell Line | 5 | 2020 | 15543 | 0.080 |
Why?
|
Inflammation | 6 | 2020 | 10850 | 0.080 |
Why?
|
Epidermal Growth Factor | 3 | 2008 | 698 | 0.080 |
Why?
|
Lipid Metabolism | 1 | 2017 | 1892 | 0.080 |
Why?
|
Cyclic AMP | 1 | 2012 | 1467 | 0.080 |
Why?
|
Drug Discovery | 1 | 2016 | 1064 | 0.080 |
Why?
|
Arteriovenous Malformations | 1 | 2011 | 397 | 0.080 |
Why?
|
Osteolysis | 1 | 2010 | 271 | 0.080 |
Why?
|
Tumor Cells, Cultured | 10 | 2018 | 6113 | 0.070 |
Why?
|
Lipocalins | 1 | 2009 | 162 | 0.070 |
Why?
|
Vascular Endothelial Growth Factors | 3 | 2016 | 754 | 0.070 |
Why?
|
Myocytes, Smooth Muscle | 1 | 2012 | 702 | 0.070 |
Why?
|
Transcription, Genetic | 3 | 1998 | 7599 | 0.070 |
Why?
|
Hyperplasia | 3 | 2003 | 1144 | 0.070 |
Why?
|
Acute-Phase Proteins | 1 | 2009 | 252 | 0.070 |
Why?
|
Fibroblast Growth Factor 2 | 3 | 1998 | 594 | 0.070 |
Why?
|
Immune Tolerance | 1 | 2017 | 2324 | 0.070 |
Why?
|
Atherosclerosis | 1 | 2023 | 3424 | 0.070 |
Why?
|
Diabetic Retinopathy | 1 | 2017 | 1299 | 0.070 |
Why?
|
Cyclohexanes | 1 | 2008 | 151 | 0.070 |
Why?
|
Male | 28 | 2021 | 363698 | 0.070 |
Why?
|
Melanoma | 7 | 2017 | 5719 | 0.070 |
Why?
|
Aspirin | 1 | 2019 | 3134 | 0.070 |
Why?
|
Angiogenesis Inducing Agents | 3 | 2014 | 254 | 0.070 |
Why?
|
Lactic Acid | 1 | 2012 | 1137 | 0.070 |
Why?
|
Sesquiterpenes | 1 | 2008 | 175 | 0.070 |
Why?
|
Endothelial Growth Factors | 2 | 2000 | 680 | 0.070 |
Why?
|
Apoptosis | 6 | 2020 | 9514 | 0.070 |
Why?
|
Up-Regulation | 1 | 2016 | 4137 | 0.070 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 3 | 2014 | 3807 | 0.070 |
Why?
|
Lymphokines | 2 | 2000 | 911 | 0.070 |
Why?
|
Spheroids, Cellular | 1 | 2008 | 328 | 0.070 |
Why?
|
Allergy and Immunology | 1 | 2008 | 169 | 0.060 |
Why?
|
Retina | 1 | 2017 | 2657 | 0.060 |
Why?
|
Immunophilins | 1 | 2005 | 20 | 0.060 |
Why?
|
Female | 26 | 2021 | 396112 | 0.060 |
Why?
|
Base Sequence | 2 | 2014 | 12403 | 0.060 |
Why?
|
PPAR alpha | 1 | 2007 | 175 | 0.060 |
Why?
|
Receptors, Notch | 1 | 2010 | 752 | 0.060 |
Why?
|
Cell Survival | 4 | 2020 | 5747 | 0.060 |
Why?
|
Fatty Acids, Unsaturated | 2 | 2019 | 538 | 0.060 |
Why?
|
Granulocytes | 1 | 2007 | 549 | 0.060 |
Why?
|
Receptor, erbB-3 | 1 | 2006 | 141 | 0.060 |
Why?
|
Osteoblasts | 1 | 2010 | 1143 | 0.060 |
Why?
|
Xenograft Model Antitumor Assays | 3 | 2018 | 3608 | 0.060 |
Why?
|
Gene Deletion | 1 | 2012 | 2666 | 0.060 |
Why?
|
Immunoblotting | 1 | 2008 | 1644 | 0.060 |
Why?
|
Endothelium, Vascular | 4 | 2013 | 4427 | 0.060 |
Why?
|
Genetic Vectors | 3 | 2005 | 3404 | 0.060 |
Why?
|
Molecular Sequence Data | 3 | 2014 | 17594 | 0.050 |
Why?
|
Graft Rejection | 1 | 2017 | 4499 | 0.050 |
Why?
|
Cell Death | 2 | 2021 | 1679 | 0.050 |
Why?
|
In Situ Nick-End Labeling | 1 | 2004 | 610 | 0.050 |
Why?
|
Cell Adhesion | 2 | 2013 | 3089 | 0.050 |
Why?
|
Intestines | 1 | 2012 | 1906 | 0.050 |
Why?
|
Intestinal Mucosa | 2 | 2012 | 3046 | 0.050 |
Why?
|
Intercellular Junctions | 1 | 2023 | 198 | 0.050 |
Why?
|
Colorectal Neoplasms | 1 | 2023 | 6942 | 0.050 |
Why?
|
Trypsinogen | 1 | 2022 | 84 | 0.050 |
Why?
|
Tumor Suppressor Proteins | 1 | 2012 | 2796 | 0.050 |
Why?
|
Thalidomide | 1 | 2008 | 886 | 0.050 |
Why?
|
Biomimetics | 1 | 2023 | 168 | 0.050 |
Why?
|
Carbachol | 1 | 2022 | 223 | 0.050 |
Why?
|
Trypsin | 1 | 2022 | 487 | 0.050 |
Why?
|
Myocardial Infarction | 1 | 2022 | 11499 | 0.050 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2012 | 2900 | 0.050 |
Why?
|
T-Lymphocytes | 1 | 2019 | 10261 | 0.050 |
Why?
|
History, 21st Century | 1 | 2008 | 1574 | 0.050 |
Why?
|
Gene Expression | 1 | 2014 | 7584 | 0.050 |
Why?
|
Carcinoma, Transitional Cell | 2 | 2006 | 790 | 0.050 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2019 | 9373 | 0.040 |
Why?
|
Aflatoxin B1 | 1 | 2020 | 17 | 0.040 |
Why?
|
Gene Silencing | 3 | 2012 | 1505 | 0.040 |
Why?
|
Neoplastic Processes | 1 | 2020 | 35 | 0.040 |
Why?
|
Neoplasm Transplantation | 4 | 2010 | 2014 | 0.040 |
Why?
|
Endothelium | 2 | 2016 | 767 | 0.040 |
Why?
|
Nanoparticles | 1 | 2012 | 1964 | 0.040 |
Why?
|
Breast Neoplasms | 4 | 2011 | 21056 | 0.040 |
Why?
|
Antibodies, Monoclonal | 1 | 2017 | 9249 | 0.040 |
Why?
|
Melanoma, Experimental | 2 | 2017 | 558 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2018 | 10729 | 0.040 |
Why?
|
Bone and Bones | 1 | 2010 | 2554 | 0.040 |
Why?
|
Hematocrit | 1 | 2021 | 621 | 0.040 |
Why?
|
History, 20th Century | 1 | 2008 | 2761 | 0.040 |
Why?
|
RNA, Messenger | 6 | 2017 | 12768 | 0.040 |
Why?
|
Plasminogen Inactivators | 1 | 2019 | 37 | 0.040 |
Why?
|
Models, Animal | 1 | 2006 | 2120 | 0.040 |
Why?
|
Mice, SCID | 3 | 2019 | 2630 | 0.040 |
Why?
|
Stem Cells | 1 | 2011 | 3540 | 0.040 |
Why?
|
Carcinoma, Hepatocellular | 2 | 2021 | 2329 | 0.040 |
Why?
|
Surface-Active Agents | 1 | 2018 | 150 | 0.040 |
Why?
|
Transforming Growth Factor beta1 | 2 | 2013 | 637 | 0.040 |
Why?
|
Oligonucleotide Probes | 1 | 1998 | 417 | 0.040 |
Why?
|
Carcinogens | 1 | 2020 | 452 | 0.040 |
Why?
|
Flow Cytometry | 2 | 2020 | 5881 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor C | 1 | 2018 | 124 | 0.040 |
Why?
|
Prostaglandins | 1 | 2019 | 396 | 0.040 |
Why?
|
Bone Neoplasms | 1 | 2010 | 2567 | 0.040 |
Why?
|
Half-Life | 1 | 2018 | 644 | 0.040 |
Why?
|
Calibration | 1 | 2020 | 814 | 0.040 |
Why?
|
MicroRNAs | 1 | 2013 | 3785 | 0.040 |
Why?
|
beta Catenin | 1 | 2023 | 1043 | 0.040 |
Why?
|
Glioblastoma | 1 | 2012 | 3459 | 0.040 |
Why?
|
Platinum | 1 | 2019 | 218 | 0.040 |
Why?
|
Hirudins | 1 | 2018 | 179 | 0.030 |
Why?
|
Transcription Factor AP-1 | 1 | 2018 | 322 | 0.030 |
Why?
|
Isometric Contraction | 1 | 2017 | 149 | 0.030 |
Why?
|
Proto-Oncogene Proteins | 1 | 2009 | 4520 | 0.030 |
Why?
|
Phosphatidylserines | 1 | 2017 | 184 | 0.030 |
Why?
|
Fibrosis | 1 | 2023 | 2070 | 0.030 |
Why?
|
Administration, Intranasal | 1 | 2018 | 482 | 0.030 |
Why?
|
Amino Sugars | 1 | 1996 | 39 | 0.030 |
Why?
|
Cyclization | 1 | 2016 | 60 | 0.030 |
Why?
|
Fibrosarcoma | 1 | 1998 | 313 | 0.030 |
Why?
|
Lipoxins | 1 | 2019 | 419 | 0.030 |
Why?
|
Drug Design | 1 | 2021 | 1042 | 0.030 |
Why?
|
RNA Interference | 1 | 2004 | 2832 | 0.030 |
Why?
|
Glucosamine | 1 | 1996 | 128 | 0.030 |
Why?
|
Medical Oncology | 1 | 2008 | 2339 | 0.030 |
Why?
|
src-Family Kinases | 1 | 2018 | 538 | 0.030 |
Why?
|
Retroviridae | 1 | 1998 | 847 | 0.030 |
Why?
|
Urinary Bladder Neoplasms | 2 | 2006 | 2176 | 0.030 |
Why?
|
Cell Adhesion Molecules | 2 | 2013 | 1612 | 0.030 |
Why?
|
Taxoids | 1 | 2019 | 665 | 0.030 |
Why?
|
Endocytosis | 1 | 2020 | 951 | 0.030 |
Why?
|
Perfusion | 1 | 2020 | 1407 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2018 | 561 | 0.030 |
Why?
|
Molecular Targeted Therapy | 2 | 2017 | 2822 | 0.030 |
Why?
|
Cell Growth Processes | 2 | 2006 | 381 | 0.030 |
Why?
|
Urodynamics | 1 | 2017 | 349 | 0.030 |
Why?
|
Respiratory Mucosa | 1 | 1998 | 438 | 0.030 |
Why?
|
Time Factors | 3 | 2004 | 40065 | 0.030 |
Why?
|
Mucous Membrane | 1 | 1998 | 657 | 0.030 |
Why?
|
Repressor Proteins | 1 | 2005 | 2968 | 0.030 |
Why?
|
Fluorescent Antibody Technique | 1 | 1999 | 2476 | 0.030 |
Why?
|
Nitric Oxide Synthase | 1 | 1997 | 911 | 0.030 |
Why?
|
Chemokines | 1 | 2019 | 956 | 0.030 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2018 | 647 | 0.030 |
Why?
|
Staining and Labeling | 1 | 1998 | 1072 | 0.030 |
Why?
|
Tissue Array Analysis | 1 | 2016 | 545 | 0.030 |
Why?
|
Nanomedicine | 1 | 2017 | 286 | 0.030 |
Why?
|
Pigmentation | 1 | 2014 | 143 | 0.030 |
Why?
|
Fibroblasts | 1 | 2004 | 4159 | 0.030 |
Why?
|
Keratin-18 | 1 | 2013 | 37 | 0.030 |
Why?
|
Respiratory Function Tests | 1 | 2018 | 1693 | 0.030 |
Why?
|
Microtubule-Associated Proteins | 1 | 2019 | 1066 | 0.030 |
Why?
|
Exercise Test | 1 | 2021 | 2180 | 0.030 |
Why?
|
Liver Cirrhosis | 1 | 2023 | 1959 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2020 | 1789 | 0.030 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 3251 | 0.030 |
Why?
|
Vimentin | 1 | 2013 | 258 | 0.030 |
Why?
|
Annexin A2 | 1 | 2012 | 43 | 0.030 |
Why?
|
Bone Marrow Cells | 2 | 2013 | 2412 | 0.030 |
Why?
|
Receptor, TIE-2 | 1 | 2013 | 183 | 0.030 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2018 | 1140 | 0.030 |
Why?
|
Extracellular Matrix | 1 | 2020 | 1727 | 0.020 |
Why?
|
Growth Substances | 2 | 2005 | 758 | 0.020 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2000 | 2844 | 0.020 |
Why?
|
Tumor Burden | 1 | 2017 | 1885 | 0.020 |
Why?
|
Middle Aged | 5 | 2017 | 223009 | 0.020 |
Why?
|
Gene Expression Regulation | 2 | 2006 | 11888 | 0.020 |
Why?
|
Antibodies | 1 | 1999 | 2417 | 0.020 |
Why?
|
Kinetics | 1 | 1998 | 6274 | 0.020 |
Why?
|
Oligonucleotides, Antisense | 1 | 2013 | 462 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 1997 | 1410 | 0.020 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 1 | 2011 | 246 | 0.020 |
Why?
|
Carcinogenicity Tests | 2 | 2002 | 39 | 0.020 |
Why?
|
Reactive Oxygen Species | 1 | 2018 | 2140 | 0.020 |
Why?
|
Microscopy, Electron, Scanning | 1 | 2012 | 939 | 0.020 |
Why?
|
Sampling Studies | 1 | 2011 | 607 | 0.020 |
Why?
|
Transcription Factors | 2 | 2009 | 12131 | 0.020 |
Why?
|
Macular Degeneration | 1 | 2017 | 1014 | 0.020 |
Why?
|
Amino Acids | 1 | 2016 | 1709 | 0.020 |
Why?
|
Mutation | 1 | 2014 | 30198 | 0.020 |
Why?
|
Chromatography, Liquid | 1 | 2013 | 990 | 0.020 |
Why?
|
Heart | 1 | 2022 | 4414 | 0.020 |
Why?
|
Metabolomics | 1 | 2019 | 1668 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 1 | 2006 | 5696 | 0.020 |
Why?
|
ADAM Proteins | 1 | 2011 | 242 | 0.020 |
Why?
|
Leukocytes | 1 | 2017 | 2027 | 0.020 |
Why?
|
Eye | 1 | 2013 | 710 | 0.020 |
Why?
|
Phosphorylation | 3 | 2008 | 8278 | 0.020 |
Why?
|
Inflammation Mediators | 1 | 2017 | 1884 | 0.020 |
Why?
|
Cadherins | 1 | 2013 | 900 | 0.020 |
Why?
|
DNA, Complementary | 2 | 2004 | 1984 | 0.020 |
Why?
|
Nitric Oxide | 1 | 1997 | 2143 | 0.020 |
Why?
|
Tyrphostins | 1 | 2008 | 63 | 0.020 |
Why?
|
Cinnamates | 1 | 2008 | 59 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2020 | 3564 | 0.020 |
Why?
|
Lipids | 1 | 2019 | 3315 | 0.020 |
Why?
|
Oligopeptides | 1 | 2013 | 1192 | 0.020 |
Why?
|
Radiation Chimera | 1 | 2007 | 216 | 0.020 |
Why?
|
Tandem Mass Spectrometry | 1 | 2013 | 1192 | 0.020 |
Why?
|
Lung Neoplasms | 4 | 2002 | 13451 | 0.020 |
Why?
|
Cloning, Molecular | 2 | 2004 | 4165 | 0.020 |
Why?
|
Carcinoma, Lewis Lung | 1 | 2007 | 106 | 0.020 |
Why?
|
Proteomics | 1 | 2020 | 3910 | 0.020 |
Why?
|
Regression Analysis | 1 | 2016 | 6322 | 0.020 |
Why?
|
Isoenzymes | 1 | 2011 | 1689 | 0.020 |
Why?
|
Coculture Techniques | 1 | 2010 | 1336 | 0.020 |
Why?
|
DNA Primers | 1 | 2010 | 2825 | 0.020 |
Why?
|
NF-kappa B | 1 | 2014 | 2485 | 0.020 |
Why?
|
Calcium | 1 | 1999 | 5767 | 0.020 |
Why?
|
Mesoderm | 1 | 2009 | 679 | 0.020 |
Why?
|
Peptide Fragments | 1 | 2018 | 5125 | 0.020 |
Why?
|
Antigens, Neoplasm | 1 | 2013 | 2002 | 0.020 |
Why?
|
Cell Line, Transformed | 1 | 2007 | 858 | 0.020 |
Why?
|
Protein Binding | 2 | 2012 | 9296 | 0.020 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2008 | 612 | 0.020 |
Why?
|
Oxygen | 1 | 2017 | 4241 | 0.020 |
Why?
|
Actins | 1 | 2012 | 2056 | 0.020 |
Why?
|
Glucose | 1 | 2017 | 4335 | 0.020 |
Why?
|
Corneal Neovascularization | 1 | 2007 | 184 | 0.020 |
Why?
|
Estrogen Receptor alpha | 1 | 2009 | 578 | 0.010 |
Why?
|
Cytotoxicity, Immunologic | 2 | 1999 | 1347 | 0.010 |
Why?
|
Carcinoma | 1 | 1996 | 2312 | 0.010 |
Why?
|
Quantum Dots | 1 | 2006 | 168 | 0.010 |
Why?
|
Adipose Tissue | 1 | 2016 | 3312 | 0.010 |
Why?
|
Reference Values | 1 | 2011 | 4908 | 0.010 |
Why?
|
Survival Rate | 1 | 2018 | 12795 | 0.010 |
Why?
|
Pancreatic Neoplasms | 1 | 2021 | 5444 | 0.010 |
Why?
|
Organ Culture Techniques | 1 | 2006 | 788 | 0.010 |
Why?
|
Environmental Exposure | 1 | 1998 | 4544 | 0.010 |
Why?
|
HEK293 Cells | 1 | 2012 | 4260 | 0.010 |
Why?
|
Cell Membrane | 1 | 2012 | 3634 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2011 | 6203 | 0.010 |
Why?
|
Ligands | 1 | 2009 | 3273 | 0.010 |
Why?
|
Carcinoma, Renal Cell | 1 | 1997 | 3181 | 0.010 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2017 | 3446 | 0.010 |
Why?
|
Aged, 80 and over | 2 | 2017 | 59489 | 0.010 |
Why?
|
Receptors, Interferon | 1 | 2002 | 114 | 0.010 |
Why?
|
Quinazolines | 1 | 2008 | 1364 | 0.010 |
Why?
|
Receptor, Interferon alpha-beta | 1 | 2002 | 113 | 0.010 |
Why?
|
Adult | 4 | 2017 | 223044 | 0.010 |
Why?
|
Kidney Neoplasms | 1 | 1997 | 4274 | 0.010 |
Why?
|
Aged | 3 | 2017 | 171117 | 0.010 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2004 | 1240 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2008 | 2453 | 0.010 |
Why?
|
Killer Cells, Natural | 2 | 1999 | 2210 | 0.010 |
Why?
|
Algorithms | 1 | 2020 | 14071 | 0.010 |
Why?
|
Bone Marrow Transplantation | 1 | 2007 | 2729 | 0.010 |
Why?
|
Microscopy, Fluorescence | 1 | 2006 | 2627 | 0.010 |
Why?
|
Infant, Newborn | 1 | 1999 | 26346 | 0.010 |
Why?
|
Mice, Mutant Strains | 1 | 2002 | 1745 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2016 | 22223 | 0.010 |
Why?
|
Kidney | 1 | 2013 | 7066 | 0.010 |
Why?
|
Young Adult | 2 | 2017 | 59889 | 0.010 |
Why?
|
Prognosis | 1 | 2018 | 29922 | 0.010 |
Why?
|
Enzyme Inhibitors | 1 | 2008 | 3715 | 0.010 |
Why?
|
Introns | 1 | 2000 | 966 | 0.010 |
Why?
|
CHO Cells | 1 | 2000 | 1372 | 0.010 |
Why?
|
Receptor, erbB-2 | 1 | 2008 | 2593 | 0.010 |
Why?
|
Rats | 2 | 2006 | 23707 | 0.010 |
Why?
|
DNA Fragmentation | 1 | 1997 | 238 | 0.010 |
Why?
|
Galactosides | 1 | 1996 | 54 | 0.010 |
Why?
|
Tumor Stem Cell Assay | 1 | 1996 | 116 | 0.010 |
Why?
|
Cricetinae | 1 | 2000 | 2411 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2011 | 14652 | 0.010 |
Why?
|
Child | 2 | 2017 | 80564 | 0.010 |
Why?
|
Nitric Oxide Synthase Type II | 1 | 1997 | 512 | 0.010 |
Why?
|
Adolescent | 2 | 2017 | 88835 | 0.010 |
Why?
|
Sepharose | 1 | 1996 | 100 | 0.010 |
Why?
|
Colony-Forming Units Assay | 1 | 1996 | 351 | 0.010 |
Why?
|
Tissue Distribution | 1 | 2000 | 2266 | 0.010 |
Why?
|
Carbohydrate Sequence | 1 | 1996 | 410 | 0.010 |
Why?
|
Tyrosine | 1 | 2000 | 1428 | 0.010 |
Why?
|
Protein Isoforms | 1 | 2000 | 1718 | 0.010 |
Why?
|
Transforming Growth Factor alpha | 1 | 1995 | 134 | 0.010 |
Why?
|
Binding, Competitive | 1 | 1996 | 1140 | 0.010 |
Why?
|
Lectins | 1 | 1996 | 487 | 0.010 |
Why?
|
Chromosomes, Human, Pair 7 | 1 | 1995 | 311 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2009 | 11206 | 0.010 |
Why?
|
Gene Transfer Techniques | 1 | 1999 | 1216 | 0.010 |
Why?
|
Interleukin-1 | 1 | 1997 | 1243 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2011 | 15880 | 0.010 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2017 | 12240 | 0.010 |
Why?
|
Genetic Engineering | 1 | 1998 | 933 | 0.010 |
Why?
|
Spleen | 1 | 1998 | 2296 | 0.010 |
Why?
|
Triazoles | 1 | 1997 | 897 | 0.010 |
Why?
|
Molecular Structure | 1 | 1996 | 1885 | 0.010 |
Why?
|
Structure-Activity Relationship | 1 | 1996 | 3051 | 0.010 |
Why?
|
Interferon-gamma | 1 | 1997 | 3160 | 0.000 |
Why?
|
Mass Spectrometry | 1 | 1996 | 2194 | 0.000 |
Why?
|
Retrospective Studies | 1 | 2016 | 81514 | 0.000 |
Why?
|
Adenocarcinoma | 1 | 2004 | 6364 | 0.000 |
Why?
|
Chromosome Mapping | 1 | 1995 | 4618 | 0.000 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 1996 | 3672 | 0.000 |
Why?
|